Cadrenal Therapeutics, Inc. (CVKD) — Institutional Holders, Q2 2026
20 institutional investment managers reported a CVKD position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $379.9K. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
CVKD in Q2 2026: what funds did
Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
Biggest buyers
- HRT FINANCIALNew · +29,055 sh+$97.0K
- VANGUARD CAPITAL MANAGEMENTAdded · +4,936 sh+$16.5K
- CoreCap AdvisorsNew · +1,285 sh+$4.3K
- UBS Group AGNew · +1,112 sh+$3.7K
- Grove BankNew · +1,000 sh+$3.3K
Biggest sellers
- JPMORGAN CHASESold out · -7,500 sh-$25.1K
- BlackRockSold out · -5,496 sh-$18.4K
- GEODE CAPITAL MANAGEMENTTrimmed · -2,602 sh-$8.7K
- Cygnus Capital AdvisorsSold out · -1,492 sh-$5.0K
- Destiny Wealth PartnersSold out · -200 sh-$668.00
CVKD 13F holders ranked 1–20 of 20
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT#1 · 50,137 sh | 50,137 | $167.5K | 0.00% | +10.9% |
| 2 | HRT FINANCIAL#2 · 29,055 sh | 29,055 | $97.0K | <0.01% | New |
| 3 | GEODE CAPITAL MANAGEMENT#3 · 19,024 sh | 19,024 | $63.5K | 0.00% | -12.0% |
| 4 | VANGUARD FIDUCIARY#4 · 8,311 sh | 8,311 | $27.8K | 0.00% | 0.0% |
| 5 | CoreCap Advisors#5 · 1,285 sh | 1,285 | $4.3K | — | New |
| 6 | Tower Research Capital (TRC)#6 · 1,282 sh | 1,282 | $4.3K | <0.01% | +226.2% |
| 7 | UBS Group AG#7 · 1,112 sh | 1,112 | $3.7K | 0.00% | New |
| 8 | Grove Bank#8 · 1,000 sh | 1,000 | $3.3K | — | New |
| 9 | MORGAN STANLEY#9 · 706 sh | 706 | $2.4K | 0.00% | +606.0% |
| 10 | Clearstead Advisors#10 · 650 sh | 650 | $2.2K | 0.00% | New |
| 11 | Quest 10 Wealth Builders#11 · 380 sh | 380 | $1.3K | <0.01% | New |
| 12 | OSAIC#12 · 300 sh | 300 | $1.0K | 0.00% | 0.0% |
| 13 | Rockefeller Capital Management L.P.#13 · 150 sh | 150 | $501.00 | 0.00% | 0.0% |
| 14 | WELLS FARGO & COMPANY#14 · 99 sh | 99 | $331.00 | 0.00% | 0.0% |
| 15 | BARCLAYS PLC#15 · 93 sh | 93 | $311.00 | 0.00% | New |
| 16 | Integrated Wealth Concepts#16 · 86 sh | 86 | $287.00 | 0.00% | New |
| 17 | Archer Investment#17 · 35 sh | 35 | $117.00 | 0.00% | 0.0% |
| 18 | IFP Advisors#18 · 30 sh | 30 | $100.00 | — | 0.0% |
| 19 | Farther Finance Advisors#19 · 25 sh | 25 | $84.00 | — | 0.0% |
| 20 | CALDWELL SUTTER CAPITAL#20 · 5 sh | 5 | $17.00 | 0.00% | 0.0% |
Funds that sold out of CVKD in Q2 2026 (7)
Held CVKD at the end of Q1 2026 and filed a Q2 2026 13F without it. Not in the list above, because they no longer hold it. Largest prior position first.
| Institution | Shares sold | Value in Q1 2026 |
|---|---|---|
| JPMORGAN CHASE7,500 sh | 7,500 | $31.9K |
| BlackRock5,496 sh | 5,496 | $28.1K |
| Cygnus Capital Advisors1,492 sh | 1,492 | $8.0K |
| Destiny Wealth Partners200 sh | 200 | $1.0K |
| HARBOUR INVESTMENTS100 sh | 100 | $512.00 |
| CURIO WEALTH1 sh | 1 | $5.00 |
| CITIGROUP1 sh | 1 | $5.00 |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.